There is a paucity of information about the neuropathology of vascular dementia and the clinical features of vascular dementia and Alzheimer's disease among African Americans. African Americans have a high risk of stroke and may be a high risk of vascular dementia. The research is a continuation application of an NIA-funded study entitled """"""""Studies of Dementia in the Black Aged: AD and MID"""""""" (July 1, 1991 - June 30 1996). The continuation application proposes to conduct longitudinal follow-up for three years (years 06-08) on the remaining African American study patients who were initially enrolled since 1991-1992 and who belong to one of the following two clinically diagnosed index case groups or control group, respectively: 1) Alzheimer's Disease (AD); 2) Dementia associated with stroke (referred to as vascular dementia or VaD); 3) Stroke without dementia (SWD). The primary objectives among the African American AD, VaD and SWD patients are to: 1) Accumulate enough standardized neuropathological observations, using CERAD criteria, on deceased cases and controls to validate clinical diagnoses of AD, VaD and SWD; 2) Collect standardized neuropathological observations that will explore and begin to: a) operationally define VaD neuropathologically by comparing neuropathological changes among the subgroup of VaD cases and SWD controls that do not have AD changes neuropathologically; b) operationally define mixed dementia (AD + VaD) neuropathologically by using factors that may be predictive of VaD from our VaD-SWD cases-control comparison (see 2A above) and standard neuropathological criteria for AD; 3) determine mortality rates and predictors of mortality among the cases and controls; 4) Determine the rate of decline and predictors of cognitive and functional decline among cases and controls; and 5) Profile and compare apolipoprotein E (APOE) alleles among cases and controls. Our observations, especially those that will explore the neuropathological operationally definition of VaD and mixed dementia (VaD + AD) will provide important preliminary information for the future development of a multi-center study to test the operational definition of VaD and study the natural history, treatment, and prevention of this disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG010102-08
Application #
2732519
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Project Start
1991-09-01
Project End
1999-06-30
Budget Start
1998-07-01
Budget End
1999-06-30
Support Year
8
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Rush University Medical Center
Department
Type
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60612
Pytel, P; Cochran, E J; Bonner, G et al. (2006) Vascular and Alzheimer-type pathology in an autopsy study of African-Americans. Neurology 66:433-5
Freels, Sally; Nyenhuis, David L; Gorelick, Philip B (2002) Predictors of survival in African American patients with AD, VaD, or stroke without dementia. Neurology 59:1146-53
Nyenhuis, David L; Gorelick, Philip B; Freels, Sally et al. (2002) Cognitive and functional decline in African Americans with VaD, AD, and stroke without dementia. Neurology 58:56-61
Bonner, G J; Darkwa, O K; Gorelick, P B (2000) Autopsy recruitment program for African Americans. Alzheimer Dis Assoc Disord 14:202-8
Lynch, G F; Gorelick, P B (2000) Stroke in African Americans. Neurol Clin 18:273-90
Gorelick, P B (1999) Can we save the brain from the ravages of midlife cardiovascular risk factors? Neurology 52:1114-5
Gorelick, P B; Erkinjuntti, T; Hofman, A et al. (1999) Prevention of vascular dementia. Alzheimer Dis Assoc Disord 13 Suppl 3:S131-9
Gorelick, P B; Mazzone, T (1999) Plasma lipids and stroke. J Cardiovasc Risk 6:217-21
Nyenhuis, D L; Gorelick, P B (1998) Vascular dementia: a contemporary review of epidemiology, diagnosis, prevention, and treatment. J Am Geriatr Soc 46:1437-48
Gorelick, P B; Harris, Y; Burnett, B et al. (1998) The recruitment triangle: reasons why African Americans enroll, refuse to enroll, or voluntarily withdraw from a clinical trial. An interim report from the African-American Antiplatelet Stroke Prevention Study (AAASPS). J Natl Med Assoc 90:141-5

Showing the most recent 10 out of 30 publications